Fuse Biotherapeutics: Funding, Investors & Team (Oct 2026)
Fuse Biotherapeutics is a biotech company developing next-generation immune-modulating therapeutics for patients with cancers. The company's therapeutic approach integrates the multiple steps of an immune response in a rational manner such that potent responses to danger are targeted without sacrificing natural breaks in the system that spare healthy tissues. Fuse Biotherapeutics was founded in 2021 and is headquartered in Los Angeles, CA.
Fuse Biotherapeutics has raised $2.6M across 1 funding round on record, the most recent an undisclosed round of $2.6M announced in Jul 2021.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Fuse Biotherapeutics Company Profile and Key Stats
Latest funding round on record: Jul 2021.
Fuse Biotherapeutics Funding Rounds
Fuse Biotherapeutics Founders and Leadership Team
Contact details for the Fuse Biotherapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Fuse Biotherapeutics Funding Compared to Other Biotechnology Startups
Fuse Biotherapeutics' latest round of $2.6M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Fuse Biotherapeutics in Biotechnology and Los Angeles
Companies Similar to Fuse Biotherapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Fuse Biotherapeutics Funding FAQs
What does Fuse Biotherapeutics do?
Fuse Biotherapeutics is a biotech company developing next-generation immune-modulating therapeutics for patients with cancers. The company's therapeutic approach integrates the multiple steps of an immune response in a rational manner such that potent responses to danger are targeted without sacrificing natural breaks in the system that spare healthy tissues. Fuse Biotherapeutics was founded in 2021 and is headquartered in Los Angeles, CA.
How much funding has Fuse Biotherapeutics raised?
Fuse Biotherapeutics has raised $2.6M across 1 round on record. The most recent is an undisclosed round of $2.6M announced in Jul 2021.
When did Fuse Biotherapeutics last raise funding?
Fuse Biotherapeutics' most recent funding round on record is an undisclosed round of $2.6M, announced in Jul 2021.
Who is the CEO of Fuse Biotherapeutics?
Paul Song is listed as CEO at Fuse Biotherapeutics.
Where is Fuse Biotherapeutics headquartered?
Fuse Biotherapeutics is based in Los Angeles, California, United States.
How many employees does Fuse Biotherapeutics have?
Fuse Biotherapeutics is in the 1-10 employee band.
How does Fuse Biotherapeutics' funding compare to other Biotechnology startups?
Fuse Biotherapeutics' latest round of $2.6M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Fuse Biotherapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Fuse Biotherapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.